ORLANDO, Fla., Dec. 5, 2014 (GLOBE NEWSWIRE) -- A shelf registration (commonly known as an S-3 filing) is a public offering which allows companies to offer and sell securities without having to file separate prospectuses for each raise. Typically, the maximum amount that can raised through one of these documents is $100 million. Looking at biotech and medtech stocks that filed an S-3 for the time period 1/1/2014 – 8/1/2014, the price performance has, in most cases, been dismal:
| Company | Ticker | Date S-3 Filed |
Price Change Since Filing of S-3 |
| Neuralstem | CUR | 6/6/2014 | -39.05% |
| PharmaAthene | PIP | 5/23/2014 | 5.59% |
| Heron Therapeutics | HRTX | 5/13/2014 | -32.60% |
| Cytori Therapeutics | CYTX | 5/9/2014 | -81.86% |
| Navidea Biopharmaceuticals | NAVB | 5/8/2014 | -16.78% |
| Rxi Pharmaceuticals | RXII | 4/1/2014 | -54.63% |
| Gelctin Therapeutics | GALT | 3/21/2014 | -75.06% |
| Corcept Therapeutics | CORT | 3/18/2014 | -17.89% |
| Catalyst Pharmaceutical Partners | CPRX | 1/31/2014 | 32.50% |
| Oramed Pharmaceuticals | ORMP | 1/24/2014 | -70.38% |
| Average | -35.02% | ||
| Median | -35.83% |
As of November 28, 2014
While there can be a lot of variability among biotech and medtech stocks, and other factors may have driven price performance outside of the shelf registration filing, the majority of stocks have had significant short-term price declines. Biotech and medtech companies tend to need to raise capital at greater frequencies relative to companies in other industries, and the filing of an S-3 may worry investors that company management could either raise money for projects/acquisitions that may not lead to a good return on investment, or that current projects may need more capital funding than initially anticipated. Long-term dilution is a big factor in returns for biotech and medtech stocks, and greater uncertainty in this area appears to lead to share price declines, at least over the short-term.
RedChip's Director of Research, Thomas Pfister, is a Chartered Financial Analyst. He has spent over six years researching and analyzing emerging growth companies in a variety of industries, including metals and mining, oil and gas, technology, biotechnology, and emerging market stocks. Mr. Pfister earned his B.S. degree in Finance summa cum laude from the University of Central Florida. He is a member of the CFA Institute and the academic honor society Phi Beta Kappa.
To stay up-to-date on the latest developments of the top names in microcap and small-cap stocks, download the RedChip Money Report Magazine app. To learn more visit: http://bit.ly/RAD_1.
Download the app today:
Apple iOS: http://bit.ly/AMAG_1
Google Android: http://bit.ly/GMAG_1
About RedChip Companies, Inc.
RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida; with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research™, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, Virtual Conferences, "The RedChip Money Report: Small Stocks Big Money"™ television show, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media and Blogging Services, and Webcasts. To learn more about RedChip's products and services, please visit: http://www.redchip.com/our_services.
"Discovering Tomorrow's Blue Chips Today"™